期刊文献+

LKB1, A New Biomarker in Breast Cancer

LKB1, A New Biomarker in Breast Cancer
下载PDF
导出
摘要 Breast cancer is the most common cancer in women worldwide. Estrogen signaling pathways have been identified as efficient targets of breast cancer therapy, given their key role in promoting breast tumor growth. Agents blocking estrogen-mediated pathways are routinely used in clinical applications in patients displaying estrogen-sensitive breast cancer subtypes;however intrinsic or acquired resistance to treatment often occurs or develops, thus limiting their efficacy. This limitation has highlighted an imperative need to identify new predictive biomarkers. Recent findings have highlighted a role for the Liver Kinase B1 (LKB1) in breast cancer tumorigenesis. LKB1 is a serine/threonine kinase mutated in Peutz-Jeghers syndrome (PJS), implicated in many cellular processes including energy metabolism, cell polarization and cell cycle arrest and has also been shown to play an essential role as a tumor suppressor gene by negatively regulating the mTOR pathway. This review provides an overview of previous findings and ongoing research on LKB1, and substantiates the use of this kinase as a potential prognostic and predictive biomarker of breast cancer. Breast cancer is the most common cancer in women worldwide. Estrogen signaling pathways have been identified as efficient targets of breast cancer therapy, given their key role in promoting breast tumor growth. Agents blocking estrogen-mediated pathways are routinely used in clinical applications in patients displaying estrogen-sensitive breast cancer subtypes;however intrinsic or acquired resistance to treatment often occurs or develops, thus limiting their efficacy. This limitation has highlighted an imperative need to identify new predictive biomarkers. Recent findings have highlighted a role for the Liver Kinase B1 (LKB1) in breast cancer tumorigenesis. LKB1 is a serine/threonine kinase mutated in Peutz-Jeghers syndrome (PJS), implicated in many cellular processes including energy metabolism, cell polarization and cell cycle arrest and has also been shown to play an essential role as a tumor suppressor gene by negatively regulating the mTOR pathway. This review provides an overview of previous findings and ongoing research on LKB1, and substantiates the use of this kinase as a potential prognostic and predictive biomarker of breast cancer.
作者 Hanine Lattouf Coralie Poulard Isabelle Treilleux Nader Hussein Mona Diab-Assaf Muriel Le Romancer Hanine Lattouf;Coralie Poulard;Isabelle Treilleux;Nader Hussein;Mona Diab-Assaf;Muriel Le Romancer(Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France;CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France;Université Lyon 1, Lyon, France;Laboratory of Molecular and Cellular Biology, Doctoral School of Sciences and Technologies, Lebanese University, Beirut, Lebanon;Department of Biochemistry and Molecular Biology, Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA;Centre Léon Bérard, Pathology Department, Lyon, France)
出处 《Journal of Cancer Therapy》 2016年第10期690-699,共20页 癌症治疗(英文)
关键词 LKB1 BIOMARKER Breast Cancer Estrogen Signaling LKB1 Biomarker Breast Cancer Estrogen Signaling
  • 相关文献

参考文献1

二级参考文献3

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部